![](/img/cover-not-exists.png)
113P A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer
Kotecki, N, O'Neil, B, Jalal, S, Massard, C, Wallin, J, Szpurka, A, Wang, D, Galvao, V Regnier, Xia, M S, Crowe, K, Geeganage, S, Doman, T, Gandhi, L, Xu, X, Bendell, JVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz451.021
Date:
December, 2019
File:
PDF, 92 KB
2019